DWTX: Licenses SP16 for Treatment of Cancer Related Pain…

About this update from Dogwood Therapeutics, Inc.

[{"type":"text","content":"By David Bautz, PhD","length":19,"tagName":"p"},{"type":"text","content":"NASDAQ:DWTX","length":11,"tagName":"p"},{"type":"text","content":"READ THE FULL DWTX RESEARCH REPORT","length":34,"tagName":"p"},{"type":"text","content":"Business Update","length":15,"tagName":"p"},{"type":"text","content":"All-Stock Licensing Deal for Treatment of Cancer Related Pain","length":61,"tagName":"p"},{"type":"text","content":"On September 29, 2025, Dogwood Therapeutics, Inc. (NASDAQ:DWTX) announced a royalty-free, global license deal with Serpin Pharma for SP16 for the management of cancer related pain (CRP), including a broad range of chemotherapy induced neuropathy symptoms. SP16 is an intravenously administered peptide that functions as an LRP1 agonist and has shown anti-inflammatory and neural repair activity. A Phase 1b trial of SP16 in Chemotherapy Induced Peripheral Neuropathy (CIPN) is scheduled to initiate in the first half of 2026 and is fully funded by the National Cancer Institute (NCI).","length":584,"tagName":"p"},{"type":"text","content":"Background on SP16","length":18,"tagName":"p"},{"type":"text","content":"SP16 is a 17 amino acid peptide that contains the active portion of Alpha 1 antitrypsin (A1AT) that binds to LDL-receptor related protein-1 (LRP1). LRP1 is a signaling and endocytic receptor that is vital for proper immune system responses, has potent anti-inflammatory properties, and is expressed on virtually all cell types. Multiple studies have shown how loss of LRP1 function can promote inflammation and neuropathic pain. Loss of LRP1 in microglia enhances experimental autoimmune encephalomyelitis in mice (Chuang et al., 2016), and genetic deletion of LRP1 in Schwann cells increases the extent and magnitude of neuropathic pain before and after injury (Orita et al., 2013). Binding of SP16 to LRP1 activates pAKT and pERK signaling that increases expression of the anti-inflammatory cytokine IL-10 (Wang et al., 2022). In addition, SP16 binding to LRP1 down regulates the expression of NF-κB, which leads to decreased expression of pro-inflammatory mediators IL-6, IL-8, IL-1β, and TNF-α (Soler et al., 2023). These results are summarized in the figure below.","length":1074,"tagName":"p"},{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","className":"","disableSlideshowImg":false,"size":{"original":{"wi...

More updates from Dogwood Therapeutics, Inc.